tradingkey.logo

Intelligent Bio Solutions Inc

INBS

1.490USD

+0.020+1.36%
Horarios del mercado ETCotizaciones retrasadas 15 min
10.12MCap. mercado
PérdidaP/E TTM

Intelligent Bio Solutions Inc

1.490

+0.020+1.36%
Más Datos de Intelligent Bio Solutions Inc Compañía
Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
Información de la empresa
Símbolo de cotizaciónINBS
Nombre de la empresaIntelligent Bio Solutions Inc
Fecha de salida a bolsaDec 23, 2020
Director ejecutivoMr. Harry Simeonidis
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 23
Dirección135 W 41St St,
CiudadNEW YORK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal10036
Teléfono16467905756
Sitio Webhttps://ibs.inc/
Símbolo de cotizaciónINBS
Fecha de salida a bolsaDec 23, 2020
Director ejecutivoMr. Harry Simeonidis
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Harry Simeonidis
Mr. Harry Simeonidis
President, Chief Executive Officer
President, Chief Executive Officer
40.41K
+0.15%
Mr. Jonathan S. Hurd
Mr. Jonathan S. Hurd
Independent Director
Independent Director
63.00
--
Mr. Valter Pinto
Mr. Valter Pinto
Managing Director
Managing Director
--
--
Dr. Steven Boyages, Ph.D.
Dr. Steven Boyages, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Spiro Sakiris
Mr. Spiro Sakiris
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nicola Fraser
Ms. Nicola Fraser
Independent Director
Independent Director
--
--
Mr. Jason Isenberg
Mr. Jason Isenberg
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Harry Simeonidis
Mr. Harry Simeonidis
President, Chief Executive Officer
President, Chief Executive Officer
40.41K
+0.15%
Mr. Jonathan S. Hurd
Mr. Jonathan S. Hurd
Independent Director
Independent Director
63.00
--
Mr. Valter Pinto
Mr. Valter Pinto
Managing Director
Managing Director
--
--
Dr. Steven Boyages, Ph.D.
Dr. Steven Boyages, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Spiro Sakiris
Mr. Spiro Sakiris
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nicola Fraser
Ms. Nicola Fraser
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United Kingdom
692.16K
94.96%
Other
31.43K
4.31%
Australia
5.28K
0.72%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 9 de jul
Actualizado: mié., 9 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Alyeska Investment Group, L.P.
8.26%
Altium Capital Management LP
2.01%
Sakiris (Spiro Kevin)
0.73%
Geode Capital Management, L.L.C.
0.66%
Simeonidis (Harry)
0.54%
Other
87.81%
Accionistas
Accionistas
Proporción
Alyeska Investment Group, L.P.
8.26%
Altium Capital Management LP
2.01%
Sakiris (Spiro Kevin)
0.73%
Geode Capital Management, L.L.C.
0.66%
Simeonidis (Harry)
0.54%
Other
87.81%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
8.26%
Investment Advisor/Hedge Fund
2.67%
Individual Investor
1.27%
Investment Advisor
0.73%
Research Firm
0.17%
Venture Capital
0.13%
Other
86.77%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
34
983.63K
13.23%
+463.06K
2025Q1
36
981.28K
14.20%
+429.65K
2024Q4
38
214.35K
3.16%
-507.92K
2024Q3
38
390.00K
7.80%
-236.97K
2024Q2
42
449.42K
76.55%
-259.12K
2024Q1
46
732.30K
88.07%
+589.21K
2023Q4
40
172.56K
98.30%
+79.74K
2023Q3
42
49.64K
11.24%
+14.21K
2023Q2
43
60.27K
19.45%
+30.17K
2023Q1
42
45.22K
32.24%
+33.92K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Alyeska Investment Group, L.P.
613.89K
8.88%
+613.89K
--
Mar 31, 2025
Altium Capital Management LP
149.25K
2.16%
+149.25K
--
Mar 31, 2025
Sakiris (Spiro Kevin)
53.93K
0.78%
+171.00
+0.32%
Mar 18, 2025
Geode Capital Management, L.L.C.
49.01K
0.71%
+22.41K
+84.25%
Mar 31, 2025
Simeonidis (Harry)
40.41K
0.58%
+59.00
+0.15%
Mar 18, 2025
Susquehanna International Group, LLP
35.49K
0.51%
+35.49K
--
Mar 31, 2025
The Vanguard Group, Inc.
15.48K
0.22%
--
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
12.82K
0.19%
+12.82K
--
Mar 31, 2025
Ionic Ventures LLC
9.40K
0.14%
+9.40K
--
Dec 31, 2023
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Feb 09, 2023
Merger
20<1
Feb 09, 2023
Merger
20<1
Fecha
Tipo
Relación
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Feb 09, 2023
Merger
20<1
Feb 09, 2023
Merger
20<1
Feb 09, 2023
Merger
20<1
Feb 09, 2023
Merger
20<1
KeyAI